Microbubbles for a new ultrasound technique

Tiny lipid-shelled microbubbles injected in vessels may serve as an new ultrasound contrast agent to evaluate microvascular blood flow. By this microbubbles US-researcher devised a ultrasound imaging technique that can spot early signs of PAD.

Peripheral arterial diseases (PAD) is a condition in which arteriosclerosis of the blood vessels in the legs limits the blood flow, and that effects about eight million Americans and approximately the same number in the other industrialized countries – particularly those older than 65. Its presence raises the risk of a heart attack or stroke to four to five times that of the general population.
But last month researchers at Oregon Health & Science University (OHSU) published in the journal Cardiovascular Imaging, that they came up with an ultrasound imaging technique that picks up subtle early evidence of peripheral arterial disease that current conventional tests miss. Lipid-shelled microbubbles are injected intravenously as an ultrasound contrast agent to evaluate microvascular blood flow in the calf muscles of subjects' legs at rest and during exercise. These microbubbles behave and circulate in much the way red blood vessels do and they "ring" in an ultrasound field giving off a strong signal.
The test , if approved for clinical use, could lead to early treatments that would head off the serious complications that can result from PAD. The disease poses particular dangers for diabetics because of the risk of infections and gangrene that can lead to amputations and death. PAD frequently goes undiagnosed in its early to mid stages. One of the reasons for this is the lack of cost-effective diagnostic tools capable of detecting PAD before it has grown serious. By contrast, cardiologists can noninvasively detect early signs of heart disease by imaging blood flows during exercise stress tests. No equivalent stress test has been available for PAD.
 PAD is becoming a hugh problem
Lead investigator Jonathan R. Lindner, professor of cardiovascular medicine at the OHSU School of Medicine, and his associates devised such a test for use in a study involving 26 control subjects with no history of coronary disease, hypertension or diabetes, and 39 patients with symptomatic PAD, of whom 19 had type 2 diabetes. The results from blood flow imaging were compared with those from the most commonly used non-invasive diagnostic tests.
"We found that contrast-enhanced ultrasound imaging outperformed most conventional forms of diagnostics in measuring and evaluating impairment in a patient's ability to recruit blood flow in the legs during modest exercise," said Lindner. Specifically, the study found that patients with PAD had lower microvascular blood flow in their calf muscles than control subjects did after two minutes of plantar-flexion exercise in which the foot is flexed as when depressing the accelerator pedal of a car.
"Peripheral arterial disease is becoming a huge problem because of the aging of the population and the increasing incidence of diabetes," said Lindner. "But we don't have good diagnostics for it, partly because a lot of the methods we have are based on measuring what's going on in the big vessels, the arteries and veins. PAD is a complex, very diffuse disease, which often involves functional abnormalities in the microcirculation system, the tiniest small vessels that go into muscle, bone, skin and connective tissues. How well the microcirculation system is functioning is what determines how well tissue is getting fed, which is the critical issue."
Test take about five minutes
Today diagnosing PAD relies mainly on detection of abnormal pulse volumes in the lower limbs, or blood pressure differences between separate readings at the ankle and the arm (the ankle-brachial index), but these are only effective in detecting moderate-to-severe cases and do not always detect disease in the small vessels.
"The real benefit of a test like this – which only takes about five minutes to do and doesn't require anything beyond the equipment and capabilities already in place in most vascular laboratories – is their value for selecting the right therapies," said Lindner. "There are new drugs in clinical trials at OHSU and elsewhere that involve gene and stem cell therapies aimed at improving the circulation by promoting new blood vessel growth. But the symptomatic benefits you get from these therapies generally can't be evaluated by conventional tests because they don't really test tissue perfusion. If you want to look at the improvement in perfusion, why not look at perfusion?"
Further studies are needed on subjects for whom no diagnosis has yet been made. The microbubbles used in the test already are approved for human use, although the PAD test is currently an off-label application. The technique does require additional training in how to receive the microbubble signals, said Lindner, but otherwise there are few significant hurdles yet to be cleared for the test to be used in vascular clinics everywhere.
Picture: Oregon Health & Science University


Read all latest stories

Related articles


Article •

MEDICA 2008 opens its doors

When from 19 to 22 November the world's largest medical fair takes place in Dusseldorf, the entire city is in a kind of emergency state: hotels are bustin' out of their seams, traffic periodically…


Article •

Defibrillator in space

Medicine is not earthly anymore. The first defibrillator has reached the International Space Station (ISS). LIFEPAK 1000 developed by Physio-Control of Redmond will be available for NASA crew members…


Article •

Two in one: atherosclerosis test for CV risk prediction

The ankle brachial index, a ratio of blood pressure measurements used to indicate the risk of peripheral artery disease and atherosclerosis, may be useful to improve the accuracy of cardiovascular…

Related products

Subscribe to Newsletter